CoChat

Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis

Open access
Deinsberger, Julia, Reisinger, David, Weber, Benedikt · 2020 · npj Regenerative Medicine

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Abstract Pluripotent stem cells (PSCs) hold great potential for novel therapeutic approaches to regenerate or replace functionally impaired tissues. Since the introduction of the induced pluripotent stem cell technology in 2006, the number of scientific publications on this topic has constantly been increasing. However, so far no therapy based on PSCs has found its way into routine clinical use. In this study, we examined research trends related to clinical trials involving PSCs based on data obtained from ClinicalTrials.gov, the ICTRP database from the World Health Organization, as well as from a search of all individual databases that are included in the ICTRP using a multistep search algorithm. Following a stringent inclusion/exclusion procedure 131 studies remained that could be classified as clinical trials involving PSCs. The magnitude of these studies (77.1%) was observational, which implies that no cells were transplanted into patients, and only a minority of studies (22.9%) were of an interventional study type. The number of clinical trials involving induced pluripotent stem cells (iPSCs, 74.8%) was substantially higher than the one involving embryonic stem cells (ESCs, 25.2%). However, the picture changes completely when focusing on interventional studies, where in the majority (73.3%) of cases ESCs were used. Interestingly, also the study duration was significantly shorter for interventional versus observational trials (p = 0.002). When focusing on the geographical study regions, it became obvious that the greatest part of all observational trials was performed in the USA (41.6%) and in France (16.8%), while the magnitude of interventional studies was performed in Asian countries (China 36.7%, Japan 13.3%, South Korea 10.0%) and in the field of ophthalmology. In summary, these results indicate that only a limited number of trials were focusing on the actual transplantation of PSCs into patients in a rather narrow field of diagnoses. The future will tell us, if the iPSC technology will ultimately overcome the current challenges and will finally make its way into routine clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41536-020-00100-4

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Geographic distribution of studies involving human pluripotent stem cells. a Global distribution of all clinical trials involving human pluripotent stem cells. b Distribution of all clinical trials involving human pluripotent stem cells. c Global distribution of interventional clinical trials involving pluripotent stem cells. d Distribution of observational clinical trials involving pluripotent stem cells. e Global distribution of all study participants. f Global distribution of interventional clinical trials involving pluripotent stem cells. g Global distribution of observational clinical trials involving pluripotent stem cells. h Comparison between interventional and observational clinical trials and study participants. The horizontal axes have logarithmic scales of different sizes.
Fig. 1 Geographic distribution of studies involving human pluripotent stem cells. a Global distribution of all clinical trials involving human pluripotent stem cells. b Distribution of all clinical trials involving human pluripotent stem cells. c Global distribution of interventional clinical trials involving pluripotent stem cells. d Distribution of observational clinical trials involving pluripotent stem cells. e Global distribution of all study participants. f Global distribution of interventional clinical trials involving pluripotent stem cells. g Global distribution of observational clinical trials involving pluripotent stem cells. h Comparison between interventional and observational clinical trials and study participants. The horizontal axes have logarithmic scales of different sizes.CC BY · PubMed Central
Fig. 2 Disease categories targeted in clinical trials involving human pluripotent stem cells. The legend shown on the top right of Fig. 2 is color coordinated with all three pie charts. a Sub-classification of the category “non-communicable diseases”. b Distribution of clinical trials involving pluripotent stem cells dependent on the targeted disease. c Distribution of observational clinical trials dependent on the targeted disease. d Distribution of interventional clinical trials dependent on the targeted disease.
Fig. 2 Disease categories targeted in clinical trials involving human pluripotent stem cells. The legend shown on the top right of Fig. 2 is color coordinated with all three pie charts. a Sub-classification of the category “non-communicable diseases”. b Distribution of clinical trials involving pluripotent stem cells dependent on the targeted disease. c Distribution of observational clinical trials dependent on the targeted disease. d Distribution of interventional clinical trials dependent on the targeted disease.CC BY · PubMed Central
Fig. 3 Comparison of starting point and study duration dependent on the use of either one of the two stem cell types, hiPSC and hESC. The blue bars show the starting point and study duration of clinical studies involving hESCs, the orange bars depict the same information for studies involving hiPSC. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.
Fig. 3 Comparison of starting point and study duration dependent on the use of either one of the two stem cell types, hiPSC and hESC. The blue bars show the starting point and study duration of clinical studies involving hESCs, the orange bars depict the same information for studies involving hiPSC. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.CC BY · PubMed Central
Fig. 4 Comparison of starting point and (scheduled) study duration dependent on the study design. The blue bars show the starting point and study duration of observational clinical studies, the orange bars depict the same information for interventional clinical trials. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.
Fig. 4 Comparison of starting point and (scheduled) study duration dependent on the study design. The blue bars show the starting point and study duration of observational clinical studies, the orange bars depict the same information for interventional clinical trials. The green dashed line shows the time of data collection. The x axis shows the time in years, the y axis shows the study numbers. A list of the respective studies can be found in Supplementary Table 1.CC BY · PubMed Central
Fig. 5 Usage of pluripotent stem cell types (hESC and iPSC) dependent on geographic distribution and study design. a Distribution of all clinical trials and interventional and observational trials respectively, dependent on the usage of hESC or hiPSC. b Choropleth map presenting the geographic distribution of all clinical trials involving hESCs. c Choropleth map presenting the geographic distribution of all clinical trials involving hiPSCs.
Fig. 5 Usage of pluripotent stem cell types (hESC and iPSC) dependent on geographic distribution and study design. a Distribution of all clinical trials and interventional and observational trials respectively, dependent on the usage of hESC or hiPSC. b Choropleth map presenting the geographic distribution of all clinical trials involving hESCs. c Choropleth map presenting the geographic distribution of all clinical trials involving hiPSCs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 2

  1. Stoddard-Bennett T Reijo Pera R Treatment of Parkinson’s disease through personalized medicine and induced pluripotent stem cells Cells 2019 8 26 PMC6357081 30621042 · DOI · Paper page
  2. Regulation of stem cell research in Europe. Vol. 2020 (ed. Mahalatchimy, A.) (https://www.eurostemcell.org).

Cited by

See all 167

Metadata

Authors
Deinsberger, J., Reisinger, D., & Weber, B.
Affiliations
Medical University of Vienna (AT)
Corresponding author
Weber, Benedikt
Venue
npj Regenerative Medicine
Published
2020-09-11
Volume
5
Issue
1
Pages
15-15
ISSN
2057-3995 (ISSN-L)
OpenAlex
W3045676218
Cited by
158
References
63
Citations by year
2026: 5 · 2025: 15 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 30 · 2020: 2
FWCI
7.54
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Regenerative Medicine (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Vienna Science and Technology Fund (LS18-080)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
pluripotent stem cells, induced pluripotent stem cells, embryonic stem cells, clinical trials, research trends, stem cell transplantation, International Clinical Trials Registry Platform, ClinicalTrials.gov, ophthalmology, regenerative medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. https://app.cochat.ai/papers/10.1038/s41536-020-00100-4
The paper
Deinsberger, J., Reisinger, D., & Weber, B. (2020). Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. npj Regenerative Medicine. https://doi.org/10.1038/s41536-020-00100-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.